Raymond James Financial Inc. decreased its position in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 49.3% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 103,497 shares of the company's stock after selling 100,752 shares during the period. Raymond James Financial Inc.'s holdings in Moderna were worth $2,934,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds also recently modified their holdings of the company. Deutsche Bank AG increased its holdings in shares of Moderna by 54.7% during the fourth quarter. Deutsche Bank AG now owns 1,894,075 shares of the company's stock worth $78,756,000 after buying an additional 669,614 shares in the last quarter. Tang Capital Management LLC acquired a new stake in shares of Moderna in the fourth quarter valued at approximately $12,474,000. Bank of New York Mellon Corp increased its holdings in shares of Moderna by 1.8% in the first quarter. Bank of New York Mellon Corp now owns 1,918,248 shares of the company's stock valued at $54,382,000 after purchasing an additional 34,034 shares in the last quarter. Wealthfront Advisers LLC increased its holdings in shares of Moderna by 143.3% in the first quarter. Wealthfront Advisers LLC now owns 31,018 shares of the company's stock valued at $879,000 after purchasing an additional 18,268 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its holdings in shares of Moderna by 12.2% in the first quarter. Charles Schwab Investment Management Inc. now owns 2,629,865 shares of the company's stock valued at $74,557,000 after purchasing an additional 285,662 shares in the last quarter. Institutional investors and hedge funds own 75.33% of the company's stock.
Wall Street Analysts Forecast Growth
A number of analysts recently weighed in on the stock. Evercore ISI set a $32.00 price target on shares of Moderna in a report on Friday, August 1st. Morgan Stanley reissued an "equal weight" rating and issued a $32.00 price target on shares of Moderna in a report on Friday, August 1st. William Blair reissued a "market perform" rating on shares of Moderna in a report on Monday, June 2nd. Leerink Partners lowered their price target on shares of Moderna from $18.00 to $15.00 and set an "underperform" rating for the company in a report on Friday, August 22nd. Finally, JPMorgan Chase & Co. set a $26.00 price target on shares of Moderna in a report on Friday, August 1st. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, sixteen have assigned a Hold rating and four have issued a Sell rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Hold" and an average price target of $42.88.
Check Out Our Latest Research Report on MRNA
Moderna Price Performance
Shares of NASDAQ MRNA traded down $1.88 during midday trading on Friday, reaching $23.51. 31,216,613 shares of the stock were exchanged, compared to its average volume of 9,751,679. The business has a 50-day simple moving average of $28.34 and a two-hundred day simple moving average of $28.21. The company has a market capitalization of $9.15 billion, a price-to-earnings ratio of -3.12 and a beta of 1.93. Moderna, Inc. has a 12 month low of $23.15 and a 12 month high of $75.37.
Moderna (NASDAQ:MRNA - Get Free Report) last announced its quarterly earnings results on Friday, August 1st. The company reported ($2.13) earnings per share for the quarter, topping analysts' consensus estimates of ($2.99) by $0.86. The company had revenue of $142.00 million for the quarter, compared to analysts' expectations of $116.26 million. Moderna had a negative net margin of 94.31% and a negative return on equity of 25.96%. The business's quarterly revenue was down 41.1% compared to the same quarter last year. During the same period last year, the firm posted ($3.33) earnings per share. Moderna has set its FY 2025 guidance at EPS. Equities research analysts expect that Moderna, Inc. will post -9.61 earnings per share for the current fiscal year.
Moderna Profile
(
Free Report)
Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.
Recommended Stories
Before you consider Moderna, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Moderna wasn't on the list.
While Moderna currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
